HalioDx - Luminy Biotech Entreprises
Industry / private company
Location:
Marseille,
France (FR)
ISNI: -
A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020)
Mlecnik B, Bifulco C, Marliot F, Lugli A, Nagtegaal I, Hartmann A, Van Den Eynde M, et al.
Conference contribution
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020)
Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al.
Journal article, Review article
Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients (2019)
Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco C, Lugli A, Nagtegaal I, et al.
Conference contribution
MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018)
Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al.
Conference contribution
Immunoscore feasibility study in routine postsurgical pathologic review for early-stage colon cancer (CC) cases risk-assessment (2018)
Belaloui K, Malifarge E, Bohm J, Bossard C, Dienstmann R, Garcia S, Geppert CI, et al.
Conference contribution